Novavax, Inc.

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			After market 04:48:44 pm
15.5 ^USD	+2.31%		15.54	+0.26%

10:00pm	Novavax awaits FDA decision on whether its next COVID shot can be offered in US	RE
May. 23	Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	CI

Q1 2024 Earnings presentation

May 10, 2024 at 09:17 am EDT

2024-Q1-Earnings-Presentation.pdf

Attachments

Original Link
Permalink

Disclaimer

Novavax Inc. published this content on 10 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2024 13:16:09 UTC.

Latest news about Novavax, Inc.

Novavax awaits FDA decision on whether its next COVID shot can be offered in US	04:00pm	RE
Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024	May. 23	CI
B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	May. 23	MT
Novavax: 1st shipment of R21/MatrixM malaria vaccine	May. 21	CF
Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft...	May. 20
Focus on Nvidia	May. 20
Shah Capital ends campaign against Novavax board after Sanofi deal	May. 20	RE
Novavax Stockholder Shah Capital Withdraws Campaign Against Reelection of Directors	May. 20	MT
Shah Capital withdraws campaign against Novavax directors after Sanofi deal	May. 20	RE
Shah Capital withdraws campaign against three Novavax directors	May. 20	RE
Shah Capital Management Announces Withdrawal of Nominations	May. 20	CI
Transcript : Novavax, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	May. 15
Global markets live: Apple, Sony, Vodafone, Booking, Walmart...	May. 14
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Tuesday; AMC Entertainment, GameStop to Advance	May. 14	MT
Novavax Shares Pop Another 50% Following Sanofi Deal	May. 13	DJ
Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
Wall Street closes up ahead of inflation data	May. 10	RE
News Highlights : Top Company News of the Day - Friday at 5 PM ET	May. 10	DJ
News Highlights : Top Company News of the Day - Friday at 7 PM ET	May. 10	DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup	May. 10	DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls	May. 10	MT
Sector Update: Health Care Stocks Higher Late Afternoon	May. 10	MT
News Highlights : Top Company News of the Day - Friday at 3 PM ET	May. 10	DJ
Novavax shares soar on license deal with Sanofi	May. 10	RE
Novavax Surges on $1.2 Billion Sanofi Vaccine Deal	May. 10	MT

Chart Novavax, Inc.

Duration

Period

More charts

Company Profile

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâs proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 02:52 pm EDT

More Strategies

Ratings for Novavax, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.15 USD

Average target price

21.6 USD

Spread / Average Target

+42.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVAVAX, INC.	+222.92%	2.13B
MODERNA, INC.	+67.53%	62.86B
IQVIA HOLDINGS INC.	-0.77%	41.38B
LONZA GROUP AG	+45.66%	40.38B
CELLTRION, INC.	-10.72%	27.64B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.46B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.9B
BIO-TECHNE CORPORATION	+4.70%	12.67B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.27B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research